Symbols / IRWD
IRWD Chart
About
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 595.16M |
| Enterprise Value | 977.51M | Income | 24.02M | Sales | 296.15M |
| Book/sh | -1.61 | Cash/sh | 1.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 100 | IPO | — |
| P/E | 24.33 | Forward P/E | 2.51 | PEG | — |
| P/S | 2.01 | P/B | -2.27 | P/C | — |
| EV/EBITDA | 8.10 | EV/Sales | 3.30 | Quick Ratio | 1.08 |
| Current Ratio | 1.13 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.15 | EPS next Y | 1.46 | EPS Growth | — |
| Revenue Growth | -47.30% | Earnings | 2026-05-07 | ROA | 19.85% |
| ROE | — | ROIC | — | Gross Margin | 67.88% |
| Oper. Margin | 13.73% | Profit Margin | 8.11% | Shs Outstand | 163.06M |
| Shs Float | 119.18M | Short Float | 10.39% | Short Ratio | 4.16 |
| Short Interest | — | 52W High | 5.78 | 52W Low | 0.53 |
| Beta | 0.19 | Avg Volume | 4.53M | Volume | 2.55M |
| Target Price | $6.10 | Recom | Buy | Prev Close | $3.50 |
| Price | $3.65 | Change | 4.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.10
Mean price target
2. Current target
$3.65
Latest analyst target
3. DCF / Fair value
$12.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.65
Low
$3.70
High
$10.00
Mean
$6.10
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | Citizens | Market Outperform → Market Outperform | $10 |
| 2026-01-05 | main | Wells Fargo | Equal-Weight → Equal-Weight | $5 |
| 2026-01-05 | up | Citizens | Market Perform → Market Outperform | $8 |
| 2025-11-11 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-04-15 | down | Wells Fargo | Overweight → Equal-Weight | $1 |
| 2025-04-15 | down | Jefferies | Buy → Hold | $1 |
| 2025-04-14 | main | Leerink Partners | Market Perform → Market Perform | $1 |
| 2025-01-30 | main | JMP Securities | Market Outperform → Market Outperform | $14 |
| 2025-01-22 | main | Craig-Hallum | Buy → Buy | $8 |
| 2024-09-09 | init | Leerink Partners | — → Market Perform | $5 |
| 2024-08-09 | main | Wells Fargo | Overweight → Overweight | $12 |
| 2024-08-09 | main | Craig-Hallum | Buy → Buy | $10 |
| 2024-05-10 | main | Craig-Hallum | Buy → Buy | $14 |
| 2024-03-01 | main | Wells Fargo | Overweight → Overweight | $14 |
| 2024-02-16 | main | Piper Sandler | Overweight → Overweight | $21 |
| 2024-01-17 | init | Craig-Hallum | — → Buy | $21 |
| 2023-12-14 | init | Wells Fargo | — → Overweight | $20 |
| 2023-09-28 | init | JMP Securities | — → Market Outperform | $22 |
| 2023-05-23 | main | Piper Sandler | Overweight → Overweight | $19 |
| 2022-08-16 | main | Wells Fargo | — → Equal-Weight | $13 |
- Ironwood Pharma to stream Citizens Life Sciences fireside chat March 11 - Stock Titan Wed, 04 Mar 2026 21
- IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock? - Yahoo Finance hu, 12 Feb 2026 08
- Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? - Nasdaq Fri, 06 Mar 2026 13
- IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Zacks Investment Research hu, 26 Feb 2026 14
- Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat Wed, 07 Jan 2026 08
- IRONWOOD PHARMACEUTICALS ($IRWD) Releases Q4 2025 Earnings - Quiver Quantitative Wed, 25 Feb 2026 12
- Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha hu, 26 Feb 2026 08
- Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st ue, 06 Jan 2026 08
- Ironwood Pharmaceuticals Faces Operational Challenges Following Third-Quarter Earnings - StocksToTrade Sun, 22 Feb 2026 16
- Will Linzess Keep Boosting IRWD's Revenue in 2026 Following a Weak Fourth Quarter? - Bitget hu, 05 Mar 2026 22
- Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term - Yahoo Finance ue, 14 Oct 2025 07
- How to join Ironwood’s Q4 and full-year 2025 investor call - Stock Titan Wed, 18 Feb 2026 08
- Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9.5% on Analyst Upgrade - MarketBeat hu, 26 Feb 2026 08
- Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates - Nasdaq Wed, 25 Feb 2026 17
- IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? - Yahoo Finance hu, 27 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 32582 | 121586 | — | Sale at price 3.66 - 3.81 per share. | SHETZLINE MICHAEL | Officer | — | 2026-02-24 00:00:00 | D |
| 1 | 24173 | 90206 | — | Sale at price 3.66 - 3.81 per share. | SILVER RONALD | Officer | — | 2026-02-24 00:00:00 | D |
| 2 | 36492 | 136177 | — | Sale at price 3.66 - 3.81 per share. | MINARDO JOHN | Officer | — | 2026-02-24 00:00:00 | D |
| 3 | 21944 | 81888 | — | Sale at price 3.66 - 3.81 per share. | MARTINI GREGORY S. | Chief Financial Officer | — | 2026-02-24 00:00:00 | D |
| 4 | 21526 | 80328 | — | Sale at price 3.66 - 3.81 per share. | GASKINS TAMMI L | Officer | — | 2026-02-24 00:00:00 | D |
| 5 | 198283 | 739929 | — | Sale at price 3.66 - 3.81 per share. | MCCOURT THOMAS A | Chief Executive Officer | — | 2026-02-24 00:00:00 | D |
| 6 | 35416 | 162914 | — | Sale at price 4.60 per share. | SILVER RONALD | Officer | — | 2026-01-05 00:00:00 | D |
| 7 | 4178 | — | — | Stock Award(Grant) at price 0.00 per share. | DENNER ALEXANDER J | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-15 00:00:00 | D |
| 8 | 6016 | 19973 | — | Sale at price 3.32 per share. | GASKINS TAMMI L | Officer | — | 2025-11-17 00:00:00 | D |
| 9 | 11718 | — | — | Stock Award(Grant) at price 0.00 per share. | DENNER ALEXANDER J | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-15 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.25M | -544.53K | -233.89M | 55.78K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.31 |
| NormalizedEBITDA | 124.91M | 102.84M | 188.88M | 261.26M |
| TotalUnusualItems | -20.26M | -2.59M | -1.11B | 182.00K |
| TotalUnusualItemsExcludingGoodwill | -20.26M | -2.59M | -1.11B | 182.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 24.02M | 880.00K | -1.00B | 175.06M |
| ReconciledDepreciation | 1.88M | 2.01M | 1.57M | 1.42M |
| ReconciledCostOfRevenue | 0.00 | 0.00 | ||
| EBITDA | 104.65M | 100.24M | -924.87M | 261.44M |
| EBIT | 102.77M | 98.23M | -926.44M | 260.02M |
| NetInterestIncome | -28.67M | -28.57M | -2.66M | 1.90M |
| InterestExpense | 32.75M | 33.03M | 21.63M | 7.60M |
| InterestIncome | 4.08M | 4.47M | 18.97M | 9.50M |
| NormalizedIncome | 40.02M | 2.93M | -122.38M | 174.94M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 24.02M | 880.00K | -1.00B | 175.06M |
| TotalExpenses | 177.39M | 255.69M | 274.40M | 160.26M |
| TotalOperatingIncomeAsReported | 98.50M | 93.12M | -945.43M | 250.34M |
| DilutedAverageShares | 162.98M | 160.08M | 155.44M | 186.31M |
| BasicAverageShares | 161.84M | 159.08M | 155.44M | 154.37M |
| DilutedEPS | 0.15 | 0.01 | -6.45 | 0.96 |
| BasicEPS | 0.15 | 0.01 | -6.45 | 1.13 |
| DilutedNIAvailtoComStockholders | 24.02M | 880.00K | -1.00B | 179.51M |
| AverageDilutionEarnings | 0.00 | 0.00 | 4.45M | 0.00 |
| NetIncomeCommonStockholders | 24.02M | 880.00K | -1.00B | 175.06M |
| NetIncome | 24.02M | 880.00K | -1.00B | 175.06M |
| MinorityInterests | 0.00 | 29.32M | 0.00 | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | 24.02M | 880.00K | -1.03B | 175.06M |
| NetIncomeDiscontinuousOperations | 0.00 | |||
| NetIncomeContinuousOperations | 24.02M | 880.00K | -1.03B | 175.06M |
| TaxProvision | 46.01M | 64.32M | 83.49M | 77.36M |
| PretaxIncome | 70.03M | 65.20M | -948.07M | 252.42M |
| OtherIncomeExpense | -20.06M | -1.95M | -1.11B | 182.00K |
| OtherNonOperatingIncomeExpenses | 193.00K | 640.00K | ||
| SpecialIncomeCharges | -20.26M | -2.59M | -1.11B | 0.00 |
| OtherSpecialCharges | 1.10B | |||
| RestructuringAndMergernAcquisition | 20.26M | 2.59M | 18.32M | 0.00 |
| GainOnSaleOfSecurity | 19.00K | 182.00K | -1.18M | |
| NetNonOperatingInterestIncomeExpense | -28.67M | -28.57M | -2.66M | 1.90M |
| InterestExpenseNonOperating | 32.75M | 33.03M | 21.63M | 7.60M |
| InterestIncomeNonOperating | 4.08M | 4.47M | 18.97M | 9.50M |
| OperatingIncome | 118.76M | 95.72M | 168.34M | 250.34M |
| OperatingExpense | 177.39M | 255.69M | 274.40M | 160.26M |
| ResearchAndDevelopment | 95.14M | 111.42M | 116.08M | 44.27M |
| SellingGeneralAndAdministration | 82.26M | 144.27M | 158.31M | 115.99M |
| GrossProfit | 410.60M | 413.75M | ||
| CostOfRevenue | 0.00 | 0.00 | ||
| TotalRevenue | 296.15M | 351.41M | 442.74M | 410.60M |
| OperatingRevenue | 296.15M | 351.41M | 442.74M | 410.60M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 163.06M | 160.21M | 156.35M | 154.03M |
| ShareIssued | 163.06M | 160.21M | 156.35M | 154.03M |
| NetDebt | 369.22M | 495.43M | 605.72M | |
| TotalDebt | 597.80M | 599.48M | 715.54M | 415.92M |
| TangibleBookValue | -263.88M | -304.19M | -349.98M | 652.38M |
| InvestedCapital | 322.85M | 282.65M | 351.57M | 1.05B |
| WorkingCapital | 31.96M | 143.52M | -42.81M | 755.10M |
| NetTangibleAssets | -263.88M | -304.19M | -349.98M | 652.38M |
| CapitalLeaseObligations | 13.12M | 15.49M | 17.67M | 19.66M |
| CommonStockEquity | -261.83M | -301.33M | -346.30M | 652.38M |
| TotalCapitalization | 123.17M | 282.65M | 152.01M | 1.05B |
| TotalEquityGrossMinorityInterest | -261.83M | -301.33M | -346.30M | 652.38M |
| MinorityInterest | 0.00 | 0.00 | ||
| StockholdersEquity | -261.83M | -301.33M | -346.30M | 652.38M |
| GainsLossesNotAffectingRetainedEarnings | -1.06M | 923.00K | -3.03M | 0.00 |
| OtherEquityAdjustments | -1.06M | 923.00K | -3.03M | |
| RetainedEarnings | -1.67B | -1.70B | -1.70B | -696.38M |
| AdditionalPaidInCapital | 1.41B | 1.40B | 1.36B | 1.35B |
| CapitalStock | 163.00K | 160.00K | 156.00K | 154.00K |
| CommonStock | 163.00K | 160.00K | 156.00K | 154.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 658.74M | 652.24M | 817.37M | 448.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 416.52M | 613.40M | 541.27M | 422.62M |
| OtherNonCurrentLiabilities | 21.65M | 17.11M | 28.41M | 9.77M |
| LongTermDebtAndCapitalLeaseObligation | 394.87M | 596.29M | 512.85M | 412.85M |
| LongTermCapitalLeaseObligation | 9.87M | 12.30M | 14.54M | 16.60M |
| LongTermDebt | 385.00M | 583.99M | 498.31M | 396.25M |
| CurrentLiabilities | 242.22M | 38.85M | 276.10M | 25.52M |
| OtherCurrentLiabilities | 9.41M | 4.42M | 6.20M | 3.61M |
| CurrentDeferredLiabilities | 1.11M | 2.03M | 2.62M | |
| CurrentDeferredRevenue | 1.11M | 2.03M | 2.62M | |
| CurrentDebtAndCapitalLeaseObligation | 202.93M | 3.19M | 202.69M | 3.06M |
| CurrentCapitalLeaseObligation | 3.25M | 3.19M | 3.13M | 3.06M |
| CurrentDebt | 199.68M | 199.56M | 116.86M | |
| OtherCurrentBorrowings | 199.68M | 199.56M | 116.86M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.59M | 14.55M | 19.94M | 12.27M |
| PayablesAndAccruedExpenses | 17.18M | 14.66M | 44.66M | 6.58M |
| CurrentAccruedExpenses | 13.36M | 12.01M | 35.59M | 5.45M |
| InterestPayable | 4.44M | 4.77M | 5.95M | 188.00K |
| Payables | 3.83M | 2.65M | 9.07M | 1.14M |
| TotalTaxPayable | 927.00K | 521.00K | 1.24M | 656.00K |
| AccountsPayable | 2.90M | 2.13M | 7.83M | 483.00K |
| TotalAssets | 396.90M | 350.91M | 471.07M | 1.10B |
| TotalNonCurrentAssets | 122.72M | 168.54M | 237.78M | 319.89M |
| OtherNonCurrentAssets | 4.50M | 5.92M | 3.61M | 1.33M |
| NonCurrentDeferredAssets | 103.43M | 144.23M | 212.32M | 283.66M |
| NonCurrentDeferredTaxesAssets | 103.43M | 144.23M | 212.32M | 283.66M |
| NonCurrentAccountsReceivable | 14.59M | 24.00M | ||
| GoodwillAndOtherIntangibleAssets | 2.04M | 2.86M | 3.68M | 0.00 |
| OtherIntangibleAssets | 2.04M | 2.86M | 3.68M | |
| NetPPE | 12.75M | 15.52M | 18.17M | 20.31M |
| AccumulatedDepreciation | -8.01M | -8.37M | -8.89M | -10.76M |
| GrossPPE | 20.75M | 23.89M | 27.06M | 31.07M |
| Leases | 7.44M | 7.41M | 7.41M | 7.41M |
| OtherProperties | 9.34M | 11.03M | 13.91M | 15.35M |
| MachineryFurnitureEquipment | 3.97M | 5.45M | 5.74M | 8.32M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 274.18M | 182.37M | 233.29M | 780.63M |
| OtherCurrentAssets | 11.98M | 11.92M | 12.01M | 7.71M |
| HedgingAssetsCurrent | 0.00 | 1.11M | ||
| RestrictedCash | 0.00 | 1.25M | 1.25M | |
| PrepaidAssets | 8.69M | |||
| Receivables | 46.74M | 81.89M | 129.12M | 115.46M |
| AccountsReceivable | 46.74M | 81.89M | 129.12M | 115.46M |
| CashCashEquivalentsAndShortTermInvestments | 215.46M | 88.56M | 92.15M | 656.20M |
| CashAndCashEquivalents | 215.46M | 88.56M | 92.15M | 656.20M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 127.01M | 103.41M | 183.15M | 273.63M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -126.39M | -24.13M |
| RepaymentOfDebt | 0.00 | -265.00M | -100.00M | -120.70M |
| IssuanceOfDebt | 0.00 | 150.00M | 400.00M | 0.00 |
| CapitalExpenditure | -34.00K | -142.00K | -273.00K | -136.00K |
| InterestPaidSupplementalData | 30.33M | 32.56M | 13.55M | 5.75M |
| IncomeTaxPaidSupplementalData | 3.54M | 8.41M | 9.95M | 4.62M |
| EndCashPosition | 215.46M | 88.56M | 92.15M | 657.94M |
| BeginningCashPosition | 88.56M | 92.15M | 657.94M | 621.86M |
| EffectOfExchangeRateChanges | -329.00K | -32.00K | -53.00K | 0.00 |
| ChangesInCash | 127.23M | -3.56M | -565.73M | 36.07M |
| FinancingCashFlow | 216.00K | -106.97M | 277.16M | -237.55M |
| CashFlowFromContinuingFinancingActivities | 216.00K | -106.97M | 277.16M | -237.55M |
| NetOtherFinancingCharges | -2.98M | -29.20M | ||
| ProceedsFromStockOptionExercised | 216.00K | 11.01M | 6.36M | 9.54M |
| NetCommonStockIssuance | 0.00 | 0.00 | -126.39M | -24.13M |
| CommonStockPayments | 0.00 | 0.00 | -126.39M | -24.13M |
| NetIssuancePaymentsOfDebt | 0.00 | -115.00M | 300.00M | -120.70M |
| NetLongTermDebtIssuance | 0.00 | -115.00M | 300.00M | -120.70M |
| LongTermDebtPayments | 0.00 | -265.00M | -100.00M | -120.70M |
| LongTermDebtIssuance | 0.00 | 150.00M | 400.00M | 0.00 |
| InvestingCashFlow | -34.00K | -142.00K | -1.03B | -136.00K |
| CashFromDiscontinuedInvestingActivities | 0.00 | |||
| CashFlowFromContinuingInvestingActivities | -34.00K | -142.00K | -1.03B | -136.00K |
| NetBusinessPurchaseAndSale | 0.00 | -1.03B | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | -1.03B | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -34.00K | -142.00K | -273.00K | -136.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -34.00K | -142.00K | -273.00K | -136.00K |
| OperatingCashFlow | 127.04M | 103.55M | 183.43M | 273.76M |
| CashFromDiscontinuedOperatingActivities | 0.00 | |||
| CashFlowFromContinuingOperatingActivities | 127.04M | 103.55M | 183.43M | 273.76M |
| ChangeInWorkingCapital | 41.34M | 739.00K | 11.28M | 2.82M |
| ChangeInOtherCurrentLiabilities | 1.59M | -12.43M | -1.49M | 8.88M |
| ChangeInOtherCurrentAssets | 2.13M | 704.00K | 1.12M | 1.48M |
| ChangeInPayablesAndAccruedExpense | 2.10M | -34.86M | 6.50M | -18.75M |
| ChangeInAccruedExpense | -4.11M | -14.65M | -5.88M | -10.64M |
| ChangeInPayable | 6.20M | -20.21M | 12.38M | -8.12M |
| ChangeInAccountPayable | 6.20M | -20.21M | 12.38M | -8.12M |
| ChangeInPrepaidAssets | 367.00K | 89.00K | 4.22M | 3.22M |
| ChangeInInventory | 0.00 | 0.00 | ||
| ChangeInReceivables | 35.15M | 47.24M | 924.00K | 7.99M |
| ChangesInAccountReceivables | 35.15M | 47.24M | 924.00K | 7.99M |
| OtherNonCashItems | 1.67M | 1.90M | 1.10B | 1.85M |
| StockBasedCompensation | 17.25M | 29.85M | 32.01M | 27.05M |
| DeferredTax | 40.80M | 68.09M | 72.64M | 65.74M |
| DeferredIncomeTax | 40.80M | 68.09M | 72.64M | 65.74M |
| DepreciationAmortizationDepletion | 1.88M | 2.01M | 1.57M | 1.42M |
| DepreciationAndAmortization | 1.88M | 2.01M | 1.57M | 1.42M |
| AmortizationCashFlow | 400.00K | |||
| AmortizationOfIntangibles | 400.00K | |||
| Depreciation | 1.20M | 1.42M | 1.50M | |
| OperatingGainsLosses | 89.00K | 75.00K | -19.00K | -180.00K |
| GainLossOnInvestmentSecurities | -19.00K | -182.00K | 1.18M | |
| GainLossOnSaleOfPPE | 89.00K | 75.00K | 0.00 | 2.00K |
| NetIncomeFromContinuingOperations | 24.02M | 880.00K | -1.03B | 175.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IRWD
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|